Loading...
XASXPAR
Market cap96mUSD
Dec 27, Last price  
0.40AUD
1D
0.00%
1Q
110.53%
Jan 2017
5.02%
IPO
17.02%
Name

Paradigm Biopharmaceuticals Ltd

Chart & Performance

D1W1MN
XASX:PAR chart
P/E
—
P/S
2,367.35
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
14.64%
Rev. gr., 5y
-53.37%
Revenues
66k
+40.72%
001,290,5931,823,3032,682,5012,983,918020,55079,22446,76065,800
Net income
-59m
L+12.99%
-231,438-1,565,305-2,924,425-4,275,446-6,190,232-15,627,544-12,298,887-34,297,184-39,249,584-51,910,013-58,653,188
CFO
-66m
L+45.94%
-617,724-1,203,283-3,587,578-4,470,404-6,013,461-6,365,095-10,090,057-34,929,485-32,205,266-45,186,279-65,944,671
Earnings
Feb 26, 2025

Profile

Paradigm Biopharmaceuticals Limited, a drug repurposing company, engages in the research and development of therapeutic products for human use in Australia. It offers pentosan polysulfate sodium drugs in the injectable form for the treatment of osteoarthritis, mucopolysaccharidosis, ross river virus, chikungunya virus, and acute respiratory distress syndrome diseases. The company was incorporated in 2014 and is based in Melbourne, Australia.
URL
https://paradigmbiopharma.com/
IPO date
Aug 19, 2015
Employees
Domiciled in
AU
Incorporated in
AU

Valuation

Title
AUD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑062023‑062022‑062021‑062020‑062019‑062018‑062017‑062016‑062015‑03
Income
Revenues
66
40.72%
47
-40.98%
79
285.52%
Cost of revenue
65,112
60,239
48,202
Unusual Expense (Income)
NOPBT
(65,046)
(60,192)
(48,123)
NOPBT Margin
Operating Taxes
(6,047)
(7,042)
(7,763)
Tax Rate
NOPAT
(58,999)
(53,150)
(40,360)
Net income
(58,653)
12.99%
(51,910)
32.26%
(39,250)
14.44%
Dividends
Dividend yield
Proceeds from repurchase of equity
26,442
58,458
BB yield
-35.36%
-20.38%
Debt
Debt current
122
105
148
Long-term debt
357
473
938
Deferred revenue
Other long-term liabilities
107
113
76
Net debt
(17,388)
(55,801)
(38,635)
Cash flow
Cash from operating activities
(65,945)
(45,186)
(32,205)
CAPEX
65,945
Cash from investing activities
1
Cash from financing activities
28,177
62,535
70
FCF
(62,001)
(52,915)
(35,929)
Balance
Cash
17,867
56,379
39,721
Long term investments
Excess cash
17,864
56,377
39,717
Stockholders' equity
23,806
53,678
42,313
Invested Capital
6,289
454
3,289
ROIC
ROCE
EV
Common stock shares outstanding
293,284
289,678
241,819
Price
0.26
-74.24%
0.99
2.59%
0.97
-54.05%
Market cap
74,787
-73.92%
286,782
22.89%
233,355
-47.63%
EV
57,399
230,981
194,720
EBITDA
(64,900)
(60,039)
(47,930)
EV/EBITDA
Interest
14
16
29
Interest/NOPBT